4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-401237
General Counsel and Secretary sold 10,400 shares at $60.24 ($626,460)
- General Counsel and Secretary acquired 10,400 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. General Counsel and Secretary | 2026-09-22 | Option exercise 10b5-1 | +10,400 | $13.62 | $141,648 | 105,184 | D: show line 1 in the form |
| KASINGER JAMES R. General Counsel and Secretary | 2026-09-22 | Sale 10b5-1 | −10,400 | $60.24 | $626,460 | 94,784 | D: show line 2 in the form |
| Open-market sales · 10,400 sh · avg $60.24 · $626,460 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. General Counsel and Secretary | 2026-09-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,400 | 83,232 | D: show line 3 in the form |
Loading xslF345X06/ownership.xml…